This is a working overview of peptide hormone, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
== Prognosis == Dupuytren's disease has a high recurrence rate, especially when a person has so-called Dupuytren's diathesis. The term diathesis relates to certain features of Dupuytren's disease, and indicates an aggressive course of disease. The presence of all new Dupuytren's diathesis factors increases the risk of recurrent Dupuytren's disease by 71%, compared with a baseline risk of 23% in people lacking the factors. In another study the prognostic value of diathesis was evaluated. It was concluded that presence of diathesis can predict recurrence and extension. A scoring system was made to evaluate the risk of recurrence and extension, based on the following values: bilateral hand involvement, little-finger surgery, early onset of disease, plantar fibrosis, knuckle pads, and radial side involvement. Minimally invasive therapies may precede higher recurrence rates. Recurrence lacks a consensus definition. Furthermore, different standards and measurements follow from the various definitions.
== Organization and ultrastructure == In well-preserved bone studied at high magnification via electron microscopy, individual osteoblasts are shown to be connected by tight junctions, which prevent extracellular fluid passage and thus create a bone compartment separate from the general extracellular fluid. The osteoblasts are also connected by gap junctions, small pores that connect osteoblasts, allowing the cells in one cohort to function as a unit. The gap junctions also connect deeper layers of cells to the surface layer (osteocytes when surrounded by bone). This was demonstrated directly by injecting low molecular weight fluorescent dyes into osteoblasts and showing that the dye diffused to surrounding and deeper cells in the bone-forming unit. Bone is composed of many of these units, which are separated by impermeable zones with no cellular connections, called cement lines.
Curium is a common starting material for making higher transuranic and superheavy elements. Thus, bombarding 248Cm with neon (22Ne), magnesium (26Mg), or calcium (48Ca) yields isotopes of seaborgium (265Sg), hassium (269Hs and 270Hs), and livermorium (292Lv, 293Lv, and possibly 294Lv). Californium was discovered when a microgram-sized target of curium-242 was irradiated with 35 MeV alpha particles using the 60-inch (150 cm) cyclotron at Berkeley:
Recent public debates in artificial intelligence have increasingly focused on its broader societal and ethical implications. It has been argued AI will become so powerful that humanity may irreversibly lose control of it. This could, as physicist Stephen Hawking stated, "spell the end of the human race". This scenario has been common in science fiction, when a computer or robot suddenly develops a human-like "self-awareness" (or "sentience" or "consciousness") and becomes a malevolent character. These sci-fi scenarios are misleading in several ways. First, AI does not require human-like sentience to be an existential risk. Modern AI programs are given specific goals and use learning and intelligence to achieve them. Philosopher Nick Bostrom argued that if one gives almost any goal to a sufficiently powerful AI, it may choose to destroy humanity to achieve it (he used the example of an automated paperclip factory that destroys the world to get more iron for paperclips). Stuart Russell gives the example of household robot that tries to find a way to kill its owner to prevent it from being unplugged, reasoning that "you can't fetch the coffee if you're dead." (These are examples of "instrumental convergence".) In order to be safe for humanity, a superintelligence would have to be genuinely aligned with humanity's morality and values so that it is "fundamentally on our side". Second, Yuval Noah Harari argues that AI does not require a robot body or physical control to pose an existential risk. The essential parts of civilisation are not physical.
Sources: en.wikipedia.org
The Pd2(dba)3/MePhos catalytic system has been applied to late stage Suzuki cross couplings. This reaction has been conducted on a kilogram (2.2 lbs)scale, and no specific palladium-removal treatment was required as the excess imidazole present in the final amide coupling step coordinated to the Pd and generated a removable byproduct.
The price of real estate in Moscow continues to increase. The expected price averages $4,000 per square meter (11 sq ft) near the perimeter of the city or $6,500–8,000 per square meter in a prestigious district. The price sometimes exceeds $40,000 per square meter for a flat. Renting costs about $1,200 per month for a one-bedroom apartment and about $1,000 per month for a studio in the city center. A typical one-bedroom apartment in Moscow is about 30 square meters (320 square feet) in area; a typical two-bedroom apartment is 45 square meters (480 square feet); and a typical three-bedroom apartment is 70 square meters (750 square feet). Many residents cannot move out of their apartments, especially if a family lives in a two-room apartment originally granted by the state during the Soviet era. Some city residents have attempted to cope with the cost of living by renting out their apartments while staying in dachas (country houses) outside the city. In 2006, Mercer Human Resources Consulting named Moscow the world's most expensive city for expatriate employees, ahead of recurring winner Tokyo, because of the stable Russian ruble as well as increasing housing prices. Moscow also ranked first in the 2007 edition and 2008 edition of the survey. However, in 2009, Tokyo overtook Moscow, which came in third after Osaka. In 2014, according to Forbes magazine, Moscow was ranked the world's ninth most expensive city. This magazine ranked Moscow the second most expensive city the previous year.
== Structure == Mammalian GPX1, GPX2, GPX3, and GPX4 (this protein) have been shown to be selenium-containing enzymes, whereas GPX6 is a selenoprotein in humans with cysteine-containing homologues in rodents. In selenoproteins, the amino acid selenocysteine is inserted in the nascent polypeptide chain during the process of translational recoding of the UGA stop codon. GPX4 shares the amino acid motif of selenocysteine, glutamine, and tryptophan (catalytic triad) with other glutathione peroxidases.
Sources: en.wikipedia.org
Acute and chronic cerebral metabolic-vascular disorders (cerebral arteriosclerosis, thrombosis and cerebral embolism, transitory cerebral ischaemia). Acute and chronic peripheral metabolic-vascular disorders (organic and functional arteriopathies of the limbs), Raynaud's disease and other syndromes caused by altered peripheral irrigation. Migraines of vascular origin Coadjutant therapy in clinical situations accompanied by platelet hyper-aggregability, arterial tension. Corio-retinal vascular disorders: diabetic retinopathy, macular degeneration and retinal angiosclerosis Oto-vestibular problems of a vascular nature: dizziness, auditory hallucinations, hypoacusis. Dosages for known conditions are usually administered at 5–10 mg three times a day, however anti-aging preventative purposes may want to consider 5 mg once or twice a day more adequate.
=== Controversy === Public Citizen, a progressive consumer rights advocacy group, issued a letter in June 2013 urging the FDA not to approve suvorexant. In its reasoning, it cited marginal benefits and excessive potential for harm, including next-day effects like driving impairment and possible accidents. Consumer Reports also published articles encouraging consumers to avoid suvorexant due to it being expensive, having limited effectiveness, and posing safety concerns.
Since the end of the Cold War, coups have become rarer, and more likely to be followed by democratization. Coups still often simply replace one autocracy with another one (with the new autocratic regime usually more repressive, in an attempt to prevent another coup) or have no effect on regime type. As of 2017, there was debate about whether coups in autocracies should now be considered to promote democratization, on average, or if countries' chances of democratization are still unchanged or worsened by coups (since democratization can take place without a coup). One reason for the increase in the chance of democratization is that a higher proportion of coups (half of post-Cold-War coups) now take place in democracies (a higher percentage of countries are also now democracies). Democratic countries often rebound from coups quickly, restoring democracy, but coups in a democracy are a sign of poor political health, and increase the risk of future coups and loss of democracy. The dataset is small, so statistical significance varies depending on the model used, as of 2017; debate will end if data on more coups makes the pattern clear. The post-Cold-War increase in the chances of post-coup democratization may partly be due to the incentives created by international pressure and financing. US law, for instance, automatically cuts off all aid to a country if there is a military coup. According to a 2020 study, "external reactions to coups play important roles in whether coup leaders move toward authoritarianism or democratic governance.
As it affects glycogenolysis, it has been suggested that it should re-designated as GSD-XIV. Lafora disease is considered a complex neurodegenerative disease and also a glycogen metabolism disorder. Polyglucosan storage myopathies are associated with defective glycogen metabolism (Not McArdle disease, same gene but different symptoms) Myophosphorylase-a activity impaired: Autosomal dominant mutation on PYGM gene. AMP-independent myophosphorylase activity impaired, whereas the AMP-dependent activity was preserved. No exercise intolerance. Adult-onset muscle weakness. Accumulation of the intermediate filament desmin in the myofibers of the patients. Myophosphorylase comes in two forms: form 'a' is phosphorylated by phosphorylase kinase, form 'b' is not phosphorylated. Both forms have two conformational states: active (R or relaxed) and inactive (T or tense). When either form 'a' or 'b' are in the active state, then the enzyme converts glycogen into glucose-1-phosphate. Myophosphorylase-b is allosterically activated by AMP being in larger concentration than ATP and/or glucose-6-phosphate. (See Glycogen phosphorylase§Regulation). Unknown glycogenosis related to dystrophy gene deletion: patient has a previously undescribed myopathy associated with both Becker muscular dystrophy and a glycogen storage disorder of unknown aetiology.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.